Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.970
+0.007 (0.73%)
At close: Dec 5, 2025, 4:00 PM EST
1.020
+0.050 (5.14%)
After-hours: Dec 5, 2025, 7:29 PM EST

Company Description

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.

The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer’s disease, and dementia.

Nexalin Technology, Inc. is headquartered in Houston, Texas.

Nexalin Technology, Inc.
Nexalin Technology logo
Country United States
Founded 2010
IPO Date Sep 16, 2022
Industry Medical Devices
Sector Healthcare
Employees 6
CEO Mark White

Contact Details

Address:
1776 Yorktown, Suite 550
Houston, Texas 77056
United States
Phone 832 260 0222
Website nexalin.com

Stock Details

Ticker Symbol NXL
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.15
CIK Code 0001527352
CUSIP Number 65345B201
ISIN Number US65345B2016
Employer ID 27-5566468
SIC Code 3845

Key Executives

Name Position
Mark White President, Chief Executive Officer and Director
Dr. David Owens M.D. Chief Medical Officer, Member of Scientific Advisory Board and Director
Carolyn Shelton Executive Vice President of Clinical, Quality and Regulatory Affairs
John Patrick Claude Co-Founder and Director of Engineering and Development
Justin Van Fleet CPA Chief Financial Officer

Latest SEC Filings

Date Type Title
Dec 5, 2025 8-K Current Report
Nov 14, 2025 10-Q Quarterly Report
Oct 15, 2025 8-K Current Report
Oct 15, 2025 424B5 Filing
Sep 23, 2025 10-K/A [Amend] Annual report
Sep 22, 2025 8-K Current Report
Sep 19, 2025 25-NSE Filing
Sep 10, 2025 144 Filing
Aug 6, 2025 10-Q Quarterly Report
Aug 4, 2025 8-K Current Report